Healthcare resource utilisation by patients with coronary heart disease receiving a lifestyle-focused text message support program: an analysis from the TEXT ME study

Thakkar, Jay; Redfern, Julie; Khan, E.U.; Atkins, Emily; Ha, Jeffrey; Vo, Kha; Thiagalingam, Aravinda; Chow, Clara K

doi:10.1071/py17130

Cited by 3 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By providing professional technical guidance and training to community-level primary care workers, the ability to prevent and treat CHD in the community is improved, patient trust in community medical care technology is enhanced, and difficulties in seeking medical care are reduced. It is also highlighted that scientific community healthcare is of great clinical importance for maintaining health habits or behaviors, slowing the disease progression, and improving the QoL of CHD patients through regular healthcare intervention and effective follow-ups [ 28 , 29 ]. At the same time, home-based care involved in this integrated model can also markedly reduce the disease risk factors and improve the QoL [ 21 ].…”

Section: Discussionmentioning

confidence: 99%

A Quasi-Randomized Controlled Trial of an Integrated Healthcare Model for Patients with Coronary Heart Disease

Cao¹,

Xie²,

Yang³

et al. 2022

Rev. Cardiovasc. Med.

View full text Add to dashboard Cite

Background: An increasing number of coronary heart disease (CHD) patients with an aging population are demanding available and effective out-of-hospital continuous healthcare services. However, great efforts still need to be made to promote out-of-hospital healthcare services for better CHD secondary prevention. This study aims to evaluate the effectiveness of a hospital-community-family (HCF)-based integrated healthcare model on treatment outcomes, treatment compliance, and quality of life (QoL) in CHD patients. Methods: A quasirandomized controlled trial was conducted at the Department of Cardiology, a tertiary A-level hospital, Wuhan, China from January 2018 to January 2020 in accordance with the Consolidated Standards of Reporting Trials guidelines. CHD patients were enrolled from the hospital and quasi-randomly assigned to either HCF-based integrated healthcare model services or conventional healthcare services. The treatment outcomes and QoL were observed at the 12-month follow-up. Treatment compliance was observed at the 1-month and 12month follow-ups. Results: A total of 364 CHD patients were quasi-randomly assigned to either integrated healthcare model services (n = 190) or conventional healthcare services (n = 174). Treatment outcomes including relapse and readmission rate (22.6% vs 41.9%; relative risk [RR] = 0.54; 95% confidence interval [CI], 0.40-0.74; p = 0.0031), the occurrence of major cardiovascular events (19.5% vs 45.4%; RR = 0.43; 95% CI, 0.30-0.59; p = 0.0023), complication rate (19.5% vs 35.0%; RR = 0.56; 95% CI, 0.39-0.79; p = 0.0042), and the control rate of CHD risk factors (p < 0.05, average p = 0.009) at the 12-month follow-up in the intervention group were better than those of the control group. There was no significant difference in treatment compliance at the 1-month follow-up between groups (p > 0.05, average p = 0.872). Treatment compliance at the 12-month follow-up in the intervention group, including correct medication, reasonable diet, adherence to exercise, emotional control, self-monitoring, and regular re-examination, was higher than that of the control group (p < 0.05, average p = 0.007). No difference was found in the compliance with smoking cessation and alcohol restriction at the 12-month follow-up between groups (p = 0.043). QoL at the 12-month follow-up in the intervention group was better than that of the control group (86.31 ± 9.39 vs 73.02 ± 10.70, p = 0.0048). Conclusions: The integrated healthcare model effectively improves treatment outcomes, long-term treatment compliance, and QoL of patients, and could be implemented as a feasible strategy for CHD secondary prevention.

show abstract

Section: Discussionmentioning

confidence: 99%

A Quasi-Randomized Controlled Trial of an Integrated Healthcare Model for Patients with Coronary Heart Disease

Cao¹,

Xie²,

Yang³

et al. 2022

Rev. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…This was a limiting factor for studies conducted prior to or overlapping this period. 34,35 Similarly, MBS data did not include all procedures and excludes those covered by compensation systems 27 and services delivered to patients in public hospitals. 32,35 Also, MBS expenditure can't necessarily be pinpointed to a particular condition, especially in the case of general pathology tests or services.…”

Section: Limitations Of Linked Administrative Datamentioning

confidence: 99%

“…34,35 Similarly, MBS data did not include all procedures and excludes those covered by compensation systems 27 and services delivered to patients in public hospitals. 32,35 Also, MBS expenditure can't necessarily be pinpointed to a particular condition, especially in the case of general pathology tests or services. 34 Appropriate use of administrative data to measure disease prevalence needs to be considered, as some diseases may not require any medical care and, therefore, administrative data may not provide additional information.…”

Section: Limitations Of Linked Administrative Datamentioning

confidence: 99%

The use of linked administrative data in Australian randomised controlled trials: A scoping review

Fahridin,

Agarwal,

Bracken

et al. 2024

Clinical Trials

View full text Add to dashboard Cite

Background/Aims: The demand for simplified data collection within trials to increase efficiency and reduce costs has led to broader interest in repurposing routinely collected administrative data for use in clinical trials research. The aim of this scoping review is to describe how and why administrative data have been used in Australian randomised controlled trial conduct and analyses, specifically the advantages and limitations of their use as well as barriers and enablers to accessing administrative data for use alongside randomised controlled trials. Methods: Databases were searched to November 2022. Randomised controlled trials were included if they accessed one or more Australian administrative data sets, where some or all trial participants were enrolled in Australia, and where the article was published between January 2000 and November 2022. Titles and abstracts were independently screened by two reviewers, and the full texts of selected studies were assessed against the eligibility criteria by two independent reviewers. Data were extracted from included articles by two reviewers using a data extraction tool. Results: Forty-one articles from 36 randomised controlled trials were included. Trial characteristics, including the sample size, disease area, population, and intervention, were varied; however, randomised controlled trials most commonly linked to government reimbursed claims data sets, hospital admissions data sets and birth/death registries, and the most common reason for linkage was to ascertain disease outcomes or survival status, and to track health service use. The majority of randomised controlled trials were able to achieve linkage in over 90% of trial participants; however, consent and participant withdrawals were common limitations to participant linkage. Reported advantages were the reliability and accuracy of the data, the ease of long term follow-up, and the use of established data linkage units. Common reported limitations were locating participants who had moved outside the jurisdictional area, missing data where consent was not provided, and unavailability of certain healthcare data. Conclusions: As linked administrative data are not intended for research purposes, detailed knowledge of the data sets is required by researchers, and the time delay in receiving the data is viewed as a barrier to its use. The lack of access to primary care data sets is viewed as a barrier to administrative data use; however, work to expand the number of healthcare data sets that can be linked has made it easier for researchers to access and use these data, which may have implications on how randomised controlled trials will be run in future.

show abstract

“…Services provided through public hospitals such as inpatient, outpatient or emergency care were not recorded in the Stop Cancer PAIN Trial and therefore are not included in the analyses. Consistent with previous Australian healthcare resource utilisation studies, services provided to Department of Veterans Affairs beneficiaries were also excluded because of greater range of services accessible to these beneficiaries compared with the average Australian [15,[53][54][55]. Medical and allied health services were categorised consistent with the Medicare Benefits Schedule (See Table 1 in S1 Appendix for categories) [30].…”

Section: Data Linkagementioning

confidence: 99%

Treatment patterns and out-of-hospital healthcare resource utilisation by patients with advanced cancer living with pain: An analysis from the Stop Cancer PAIN trial

et al. 2023

View full text Add to dashboard Cite

Background About 70% of patients with advanced cancer experience pain. Few studies have investigated the use of healthcare in this population and the relationship between pain intensity and costs. Methods Adults with advanced cancer and scored worst pain ≥ 2/10 on a numeric rating scale (NRS) were recruited from 6 Australian oncology/palliative care outpatient services to the Stop Cancer PAIN trial (08/15-06/19). Out-of-hospital, publicly funded services, prescriptions and costs were estimated for the three months before pain screening. Descriptive statistics summarize the clinico-demographic variables, health services and costs, treatments and pain scores. Relationships with costs were explored using Spearman correlations, Mann-Whitney U and Kruskal-Wallis tests, and a gamma log-link generalized linear model. Results Overall, 212 participants had median worst pain scores of five (inter-quartile range 4). The most frequently prescribed medications were opioids (60.1%) and peptic ulcer/gastro-oesophageal reflux disease (GORD) drugs (51.6%). The total average healthcare cost in the three months before the census date was A$6,742 (95% CI $5,637, $7,847), approximately $27,000 annually. Men had higher mean healthcare costs than women, adjusting for age, cancer type and pain levels (men $7,872, women $4,493, p<0.01) and higher expenditure on prescriptions (men $5,559, women $2,034, p<0.01). Conclusions In this population with pain and cancer, there was no clear relationship between healthcare costs and pain severity. These treatment patterns requiring further exploration including the prevalence of peptic ulcer/GORD drugs, and lipid lowering agents and the higher healthcare costs for men. Trial registration ACTRN12615000064505. World Health Organisation unique trial number U1111–1164–4649. Registered 23 January 2015.

show abstract

Healthcare resource utilisation by patients with coronary heart disease receiving a lifestyle-focused text message support program: an analysis from the TEXT ME study

Cited by 3 publications

References 10 publications

A Quasi-Randomized Controlled Trial of an Integrated Healthcare Model for Patients with Coronary Heart Disease

A Quasi-Randomized Controlled Trial of an Integrated Healthcare Model for Patients with Coronary Heart Disease

The use of linked administrative data in Australian randomised controlled trials: A scoping review

Treatment patterns and out-of-hospital healthcare resource utilisation by patients with advanced cancer living with pain: An analysis from the Stop Cancer PAIN trial

Contact Info

Product

Resources

About